Wikisage, the free encyclopedia of the second generation, is digital heritage

Diacomit: Difference between revisions

From Wikisage
Jump to navigation Jump to search
m ((R))
mNo edit summary
Line 6: Line 6:


In December 2001 the European Medicines Agency (EMA) granted stiripentol orphan drug status (designation number EU/3/01/071) for the treatment of severe myoclonic epilepsy of infancy (Dravet's syndrome). On 4 January 2007, the EMA granted the drug a marketing authorisation that is valid throughout the European Union
In December 2001 the European Medicines Agency (EMA) granted stiripentol orphan drug status (designation number EU/3/01/071) for the treatment of severe myoclonic epilepsy of infancy (Dravet's syndrome). On 4 January 2007, the EMA granted the drug a marketing authorisation that is valid throughout the European Union
[[Dravet's syndrome]] does not exist data for combined therapy both valproic acid or [[clobazam]]<ref>Aras et al 2015</ref>
[[Dravet's syndrome]] does not exist data for combined therapy both valproic acid or [[clobazam]]<ref>[http://www.epilepsybehavior.com/article/S1525-5050(14)00698-2/pdf Aras et al 2015]</ref>


==ATC==
==ATC==

Revision as of 05:10, 1 April 2016

Diacomit ®contains 250 mg stiripentol[1][2]

[3]


In December 2001 the European Medicines Agency (EMA) granted stiripentol orphan drug status (designation number EU/3/01/071) for the treatment of severe myoclonic epilepsy of infancy (Dravet's syndrome). On 4 January 2007, the EMA granted the drug a marketing authorisation that is valid throughout the European Union Dravet's syndrome does not exist data for combined therapy both valproic acid or clobazam[4]

ATC

http://www.whocc.no/atc_ddd_index/?code=N03AX17